New Research Reinforces High Fusion Rates and Improved Patient Outcomes With Lanx ASPEN(R) MIS Fusion System

BROOMFIELD, Colo., March 12, 2013 (GLOBE NEWSWIRE) -- Lanx, Inc., a privately held global spine company focused on developing and commercializing innovative devices for fusion surgery, today announced new data supporting the ASPEN® MIS Fusion System as a less invasive approach to lumbar fusion, enabling solid fusion with improved post-operative outcomes and minimal complications. The research was presented at the 29th Annual Meeting of the AANS/CNS Section on Disorders of the Spine and Peripheral Nerves, held March 6-9 in Phoenix, AZ.

Dan Gladney, Chief Executive Officer, Lanx, said, "The presented studies continue to validate the ASPEN system as a truly minimally invasive fusion device, and demonstrate that its benefits extend beyond the procedure to positive postoperative outcomes. This research, coupled with the clinical experience of hundreds of surgeons throughout the world, speaks to the versatility and efficacy of the ASPEN device in meeting the needs of an aging and increasingly active population."

Researchers presented three posters highlighting clinical experiences with the ASPEN device and its impact on procedure invasiveness and postoperative outcomes:

  • Multivariate Analysis of Predictors of Length of Stay and Estimated Blood Loss as Quantitative Surrogates for the Term "Minimally Invasive" – Poster 352
    Presented by: John C. Stevenson, MD, Orthopedics Institute Gainesville, FL
    Retrospective 192-patient study found that patients who underwent posterior fusion with the ASPEN device alone experienced less blood loss, shorter length of stay and a reduced risk of perioperative complications than those who received supplemental screw fixation.
  • Clinical Outcomes and Fusion Rates After Spinous Process Fixation in an Elderly Cohort – Poster 353
    Presented by: Amir Vokshoor, MD, Institute of Neurosurgical Innovation, Marina del Rey, CA
    Data on 86 patients, with a mean age of 67 years, treated with the ASPEN system demonstrated fusion rates of 94% at six months follow-up, as well as a decreased VAS pain score (down 3.6 points) after three months that was sustained throughout the six to 12 month follow-up period.
  • Change in Sagittal Plane Alignment Following Single-Level Decompression and Posterolateral Lumbar Fusion with Aspen Interspinous Process Fixation – Poster 399
    Presented by: David Fusco, MD, Barrow Neurological Institute, Phoenix, AZ
    Prospective research assessed an initial seven patients treated with the posterior fusion ASPEN system for degenerative joint disease. Early findings showed successful fusion had been achieved at three months follow-up, with no significant impact on regional or global sagittal alignment.

The ASPEN system is currently being used in a wide range of surgical applications including posterior lumbar fusions (PLF) and interbody fusions (PLIF, TLIF, ALIF and Lateral) for the treatment of degenerative disc disease, spondylolisthesis, spinal trauma or spinal tumor. For more information, visit

About Lanx, Inc.
Lanx is one of the largest privately held global spine companies, focused on providing surgeons with innovative solutions to improve the quality of spine care. The Company develops and markets a full line of fusion devices, with a leading platform of minimally invasive technologies including its TIMBERLINE™ Lateral Fusion System and ASPEN® MIS Fusion System. Lanx is headquartered in Broomfield, CO. For more information on Lanx and its spinal surgery offerings, visit and

CONTACT: Company Contact: Steve Deitsch Chief Financial Officer (303) 443-7500 Media Lisa Cook (646) 536-7012 lcook@theruthgroup.comSource: Lanx